Wang Li

机构：Zhongshan Hospital of Xiamen University, Ningxia Medical University, Pharmaceutical Formulations (United States), Xiamen Medical College · ORCID：0000-0002-4293-8182

发表论文 287 篇 · 总被引 2618 次 · h-index 30

代表论文

• Identifying the optimal cutoff point of Ki-67 in breast cancer: a single-center experience (2023 · Journal of International Medical Research · 被引 19)
• Postprogression treatment of lenvatinib plus PD‐1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy (2023 · Cancer · 被引 19)
• Hepatic arterial infusion chemotherapy plus camrelizumab and apatinib for advanced hepatocellular carcinoma (2024 · Hepatology International · 被引 15)
• Multimodal imaging-based prediction of recurrence for unresectable HCC after downstage and resection-cohort study (2024 · International Journal of Surgery · 被引 15)
• Discovery of novel RNA viruses through analysis of fungi-associated next-generation sequencing data (2024 · BMC Genomics · 被引 13)
• Exosome‐derived miR ‐142‐5p from liver stem cells improves the progression of liver fibrosis by regulating macrophage polarization through CTSB (2023 · Environmental Toxicology · 被引 12)